---
id: herpes-b-virus_297
category: organisms
tags: [herpes-B-virus, cercopithecine-herpesvirus, macaque, zoonotic, encephalitis, occupational-exposure]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Herpes B Virus (Cercopithecine Herpesvirus 1)

**Q:** What are the clinical features and post-exposure management of Herpes B virus infection?

**A:**

**Epidemiology:**
- **Reservoir**: Asian macaques (asymptomatic shedding, analogous to HSV in humans)
- **Transmission**: Bite/scratch, mucosal contact with macaque saliva or tissue
- **At-risk populations**: Research lab workers, veterinarians, pet macaque owners
- **Human cases**: ~50 documented (since 1932), **70-80% mortality if untreated**

**Clinical Presentation:**

**Phase 1 (days-weeks post-exposure):**
- Vesicles at inoculation site
- Flu-like symptoms (fever, myalgia, headache)
- Regional lymphadenopathy

**Phase 2 (CNS involvement):**
- **Ascending flaccid paralysis** (similar to GBS)
- Hyperesthesia, ataxia, diplopia
- **Encephalomyelitis** → respiratory failure (cause of death)

**Post-Exposure Prophylaxis (PEP):**

**Immediate Wound Management (CRITICAL):**
- **Cleanse for ≥15 minutes**: soap/detergent for wounds, sterile saline for mucosal exposures
- Rationale: HSV enters nerves within 5 minutes; B virus likely similar

**Antiviral PEP (CDC Recommendations):**

| Drug | Dosing | Duration |
|------|--------|----------|
| **Valacyclovir** (preferred) | **1 g PO TID** | **14 days** |
| **Acyclovir** | 800 mg PO 5×/day | 14 days |

**Treatment of Confirmed Infection:**
- **Acyclovir 12.5-15 mg/kg IV q8h** OR **ganciclovir 5 mg/kg IV q12h**
- Must initiate **BEFORE neurologic symptoms** (ineffective once CNS involved)

**Diagnosis:**
- PCR (preferred; BSL-4 not required)
- Viral culture (requires BSL-4 facility)
- Serology (retrospective only)

**Pearl:** B virus causes >70% mortality if untreated; PEP must start immediately after macaque exposure. Think of it as "HSV with 70% mortality risk."

**Media:**

**Sources:** [PMC2901951 - B Virus Zoonotic Disease], [CDC B Virus Clinical Care 2024], [Occup Med Toxicol PEP Recommendations], [PMC6711206 - Decision Tool Lab Workers]
